Abstract

A series of diphenylpyridylethanamine (DPPE) derivatives was identified exhibiting potent CETP inhibition. Replacing the labile ester functionality in the initial lead <b>7</b> generated a series of amides and ureas. Further optimization of the DPPE series for potency resulted in the discovery of cyclopentylurea <b>15d</b>, which demonstrated a reduction in cholesterol ester transfer activity (48% of predose level) in hCETP/apoB-100 dual transgenic mice. The PK profile of <b>15d</b> was suboptimal, and further optimization of the N-terminus resulted in the discovery of amide <b>20</b> with an improved PK profile and robust efficacy in transgenic hCETP/apoB-100 mice and in hamsters. Compound <b>20</b> demonstrated no significant changes in either mean arterial blood pressure or heart rate in telemeterized rats despite sustained high exposures

    Similar works

    Full text

    thumbnail-image

    Available Versions